New drug cocktail shows promise for tough childhood leukemia
NCT ID NCT05192889
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children and young adults with acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. The study has two phases: first, finding the best dose, and second, seeing how well the combination works at clearing leukemia cells. About 35 participants will receive different drug combinations based on their cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax and navitoclax (oral drugs) combined with chemotherapy drugs like dexamethasone, vincristine, and others
- What this could lead to
- If successful, this could offer a new treatment option for children with hard-to-treat leukemia that has come back or not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with only 35 participants, so results may not apply to all patients. The drugs can cause serious side effects like low blood counts and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Personalized chemo and transplants aim to beat infant leukemia
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Engineered immune cells take aim at tough childhood leukemia
- New combo aims to wipe out hidden leukemia cells